Investigation Report on China's Alteplase Market, 2010-2019.
DUBLIN, Sept. 24, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/jb5rjg/investigation) has announced the addition of the "Investigation Report on China's Alteplase Market, 2010-2019" report to their offering.
As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery. Plasmin working by resolving fibrous protein in clots takes up a small market share while plasminogen activator represented by alteplase developed by Genentech is the mainstream product in global market. In China, only Actilyse, a life- saving injection of Boehringer- Ingelheim AG with approved indications of acute myocardial infarction, (acute) pulmonary embolism and acute ischemic stroke is available. Having been approved by over 85 countries in the world, actilyse is marketed by Boehringer- Ingelheim AG in areas outside North America and Japan, by Genentech under the trade name of Activase since 1996 in the US and by Roche since 1999 in the Canada. Ever since its appearance, actilyse has been widely used to treat acute ischemic stroke. According to this market survey, the annual sales value of alteplase in sample hospitals rose from less than CNY 12 million in 2005 to over CNY 40 million in 2014 and CAGR during this period reached 16.3%. Boehringer- Ingelheim AG (Germany) and Shandong Ahua Biopharmaceutical Co., Ltd dominate the market with the former having the largest market share of over 90% for sales value in 2014. Currently, the number of cardiovascular disease reports an increasing number of younger patients, high fatality and disability in China. According to the Report on Cardiovascular Diseases in China (2013), there are about 290 million people suffering from cardiovascular diseases. Since 2005, acute myocardial infarction has reported an increasing fatality and each year only 5% of 2.5 million patients per year can get treatment. Hence the vast market for anti- clotting drugs in China.Key Topics Covered: 1 Related Concepts of Alteplase 2 Market Profile of Alteplase in China 3 Survey on Alteplase sales in China, 2010-2014 4 Survey on Market Share of Major Alteplase Manufacturers in China, 2010-2014 5 Survey on Dosage Forms of Alteplase in China, 2010-2014 6 Reference Price of Alteplase in Chinese Hospitals in 2014 7 Major Manufacturers of Alteplase in Chinese Market, 2010-2014 8 Market Outlook of Alteplase in China, 2015-2019Companies Mentioned - Boehringer-Ingelheim AG - Shandong Ahua Biopharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/jb5rjg/investigation
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Publication:||PR Newswire Europe|
|Date:||Sep 24, 2015|
|Previous Article:||UAE Air Conditioner Market Report 2015 - Forecasts to 2021: Market Is Estimated to Reach $1,019 Million.|
|Next Article:||Industrial Control and Factory Automation Market worth 202.42 Billion USD by 2020.|